Format
Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 20

1.

Combined ALK and MDM2 inhibition increases antitumor activity and overcomes resistance in human ALK mutant neuroblastoma cell lines and xenograft models.

Wang HQ, Halilovic E, Li X, Liang J, Cao Y, Rakiec DP, Ruddy DA, Jeay S, Wuerthner JU, Timple N, Kasibhatla S, Li N, Williams JA, Sellers WR, Huang A, Li F.

Elife. 2017 Apr 20;6. pii: e17137. doi: 10.7554/eLife.17137.

2.

Neuroblastoma treatment in the post-genomic era.

Esposito MR, Aveic S, Seydel A, Tonini GP.

J Biomed Sci. 2017 Feb 8;24(1):14. doi: 10.1186/s12929-017-0319-y. Review.

3.

Research progress of neuroblastoma related gene variations.

Cao Y, Jin Y, Yu J, Wang J, Yan J, Zhao Q.

Oncotarget. 2017 Mar 14;8(11):18444-18455. doi: 10.18632/oncotarget.14408. Review.

4.

Massive parallel sequencing and digital gene expression analysis reveals potential mechanisms to overcome therapy resistance in pulmonary neuroendocrine tumors.

Walter RF, Vollbrecht C, Christoph D, Werner R, Schmeller J, Flom E, Trakada G, Rapti A, Adamidis V, Hohenforst-Schmidt W, Kollmeier J, Mairinger T, Wohlschlaeger J, Zarogoulidis P, Porpodis K, Schmidt KW, Mairinger FD.

J Cancer. 2016 Oct 25;7(15):2165-2172. eCollection 2016.

5.

Novel MDM2 inhibitor SAR405838 (MI-773) induces p53-mediated apoptosis in neuroblastoma.

Lu J, Guan S, Zhao Y, Yu Y, Wang Y, Shi Y, Mao X, Yang KL, Sun W, Xu X, Yi JS, Yang T, Yang J, Nuchtern JG.

Oncotarget. 2016 Dec 13;7(50):82757-82769. doi: 10.18632/oncotarget.12634.

6.

Nutlin-3 inhibits androgen receptor-driven c-FLIP expression, resulting in apoptosis of prostate cancer cells.

Logan IR, McClurg UL, Jones DL, O'Neill DJ, Shaheen FS, Lunec J, Gaughan L, Robson CN.

Oncotarget. 2016 Nov 15;7(46):74724-74733. doi: 10.18632/oncotarget.12542.

7.

Genetic Determinants of Cisplatin Resistance in Patients With Advanced Germ Cell Tumors.

Bagrodia A, Lee BH, Lee W, Cha EK, Sfakianos JP, Iyer G, Pietzak EJ, Gao SP, Zabor EC, Ostrovnaya I, Kaffenberger SD, Syed A, Arcila ME, Chaganti RS, Kundra R, Eng J, Hreiki J, Vacic V, Arora K, Oschwald DM, Berger MF, Bajorin DF, Bains MS, Schultz N, Reuter VE, Sheinfeld J, Bosl GJ, Al-Ahmadie HA, Solit DB, Feldman DR.

J Clin Oncol. 2016 Nov 20;34(33):4000-4007. doi: 10.1200/JCO.2016.68.7798. Epub 2016 Sep 30.

8.

Cell Proliferation in Neuroblastoma.

Stafman LL, Beierle EA.

Cancers (Basel). 2016 Jan 12;8(1). pii: E13. doi: 10.3390/cancers8010013. Review.

9.

Effect of low doses of actinomycin D on neuroblastoma cell lines.

Cortes CL, Veiga SR, Almacellas E, Hernández-Losa J, Ferreres JC, Kozma SC, Ambrosio S, Thomas G, Tauler A.

Mol Cancer. 2016 Jan 4;15:1. doi: 10.1186/s12943-015-0489-8.

10.
11.

Pre-clinical evaluation of the MDM2-p53 antagonist RG7388 alone and in combination with chemotherapy in neuroblastoma.

Chen L, Rousseau RF, Middleton SA, Nichols GL, Newell DR, Lunec J, Tweddle DA.

Oncotarget. 2015 Apr 30;6(12):10207-21.

12.

MDM2 is an important prognostic and predictive factor for platin-pemetrexed therapy in malignant pleural mesotheliomas and deregulation of P14/ARF (encoded by CDKN2A) seems to contribute to an MDM2-driven inactivation of P53.

Walter RF, Mairinger FD, Ting S, Vollbrecht C, Mairinger T, Theegarten D, Christoph DC, Schmid KW, Wohlschlaeger J.

Br J Cancer. 2015 Mar 3;112(5):883-90. doi: 10.1038/bjc.2015.27. Epub 2015 Feb 10.

13.

Structurally diverse MDM2-p53 antagonists act as modulators of MDR-1 function in neuroblastoma.

Chen L, Zhao Y, Halliday GC, Berry P, Rousseau RF, Middleton SA, Nichols GL, Del Bello F, Piergentili A, Newell DR, Lunec J, Tweddle DA.

Br J Cancer. 2014 Aug 12;111(4):716-25. doi: 10.1038/bjc.2014.325. Epub 2014 Jun 12.

14.

A cell-based high-throughput screen addressing 3'UTR-dependent regulation of the MYCN gene.

Sidarovich V, Adami V, Quattrone A.

Mol Biotechnol. 2014 Jul;56(7):631-43. doi: 10.1007/s12033-014-9739-z.

15.

Neuroblastoma and MYCN.

Huang M, Weiss WA.

Cold Spring Harb Perspect Med. 2013 Oct 1;3(10):a014415. doi: 10.1101/cshperspect.a014415. Review.

16.

p53, SKP2, and DKK3 as MYCN Target Genes and Their Potential Therapeutic Significance.

Chen L, Tweddle DA.

Front Oncol. 2012 Nov 28;2:173. doi: 10.3389/fonc.2012.00173. eCollection 2012.

17.

Galectin-3 impairment of MYCN-dependent apoptosis-sensitive phenotype is antagonized by nutlin-3 in neuroblastoma cells.

Veschi V, Petroni M, Cardinali B, Dominici C, Screpanti I, Frati L, Bartolazzi A, Gulino A, Giannini G.

PLoS One. 2012;7(11):e49139. doi: 10.1371/journal.pone.0049139. Epub 2012 Nov 9.

18.

Targeting the ubiquitin-mediated proteasome degradation of p53 for cancer therapy.

Devine T, Dai MS.

Curr Pharm Des. 2013;19(18):3248-62. Review.

19.

Redefining functional MYCN gene signatures in neuroblastoma.

Shohet JM.

Proc Natl Acad Sci U S A. 2012 Nov 20;109(47):19041-2. doi: 10.1073/pnas.1217598109. Epub 2012 Nov 8. No abstract available.

20.

Molecular mechanisms of MYCN-dependent apoptosis and the MDM2-p53 pathway: an Achille's heel to be exploited for the therapy of MYCN-amplified neuroblastoma.

Petroni M, Veschi V, Gulino A, Giannini G.

Front Oncol. 2012 Oct 12;2:141. doi: 10.3389/fonc.2012.00141. eCollection 2012.

Supplemental Content

Support Center